SLSN

Solèsence, Inc. (SLSN) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Solèsence, Inc. is a science-driven company focused on skin health, beauty, and life-science markets. The company operates as a single segment, offering engineered materials, formulation development, and commercial manufacturing. Key product categories include consumer products (prestige skin care), personal care ingredients (APIs), and advanced materials (legacy markets like coatings and diagnostics). The company is classified as a smaller reporting company and a non-accelerated filer.

Key Financial Metrics

Note: All figures in thousands except per share data and percentages.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 11.4% to $12.96 million, driven by a 22.2% drop in Consumer Products revenue ($10.03M vs $12.88M) and a 44.6% drop in Advanced Materials ($0.21M vs $0.37M). This was partially offset by a 98.4% increase in Personal Care Ingredients revenue ($2.73M vs $1.37M).
• Profitability Shift: The company reported a net loss of $0.77 million compared to a net income of $0.08 million in Q1 2025. Operating expenses increased, specifically Selling, General, and Administrative (SG&A) expenses which rose 32.8% to $2.80 million due to higher legal and employee costs.
• Cash Flow Improvement: Operating cash flow turned positive at $1.52 million, a significant improvement from the $7.22 million outflow in Q1 2025. This was driven by reductions in inventory and accounts receivable.
• Debt Reduction: Total related party debt decreased by approximately $1.72 million, primarily due to repayments on the accounts receivable line of credit.

Outlook, Risks, and Management Commentary

• Guidance: Management expects capital spending for 2026 to range between $0.5 million and $1.5 million, funded by operations, existing credit facilities, or new debt. Future margins depend on revenue volume, mix, and the ability to pass through raw material cost increases.
• Customer Concentration: The top three customers accounted for 67% of total revenue in Q1 2026 (up from 42% in Q1 2025). Customer #1 (Consumer Products) alone represented 37% of revenue.
• Key Risks:
  • Supply Agreement Contingency: An exclusive agreement with BASF (Customer #2) contains clauses that could trigger a mandatory sale of production equipment to the customer if performance requirements are not met.
  • Liquidity: The company relies heavily on related-party financing (Beachcorp, LLC and Strandler, LLC) for working capital. Cash balances are low ($0.57M) relative to operating needs.
  • Input Costs: Inflation and potential tariffs on international materials (e.g., cerium oxide, high purity zinc) pose risks to gross margins if costs cannot be passed to customers.
• Tax Position: The company holds approximately $36.9 million in federal net operating loss (NOL) carryforwards, with $30.7 million set to expire between 2026 and 2038.

Investor Verification Checklist

• Customer Concentration: Verify the stability of the top three customers, particularly the 37% revenue reliance on Customer #1.
• BASF Agreement Terms: Review the specific performance metrics in the BASF supply agreement that could trigger an equipment sale.
• Related Party Debt: Assess the terms and renewal status of the revolving credit facilities with Beachcorp, LLC and Strandler, LLC, which constitute the majority of the company's debt.
• Cash Runway: Evaluate the sufficiency of the $0.57 million cash balance against the projected $0.5M-$1.5M capital expenditure plan and ongoing operating losses.
• Inventory Valuation: Confirm the adequacy of the $2.77 million inventory reserve given the decline in Advanced Materials sales.